Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia

Seminars in Oncology

Volumn 35, Issue SUPPL. 1, 2008, Pages

  Giles, Francis J ^a   DeAngelo, Daniel J ^c   Baccarani, Michele ^d   Deininger, Michael ^e   Guilhot, François ^f   Hughes, Timothy ^g   Mauro, Michael ^e   Radich, Jerald ^h   Ottmann, Oliver ⁱ   Cortes, Jorge ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ALPHA INTERFERON; ARSENIC TRIOXIDE; AZACITIDINE; BCR ABL PROTEIN; BETA CATENIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DNA; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; INITIATION FACTOR 5A; MICRORNA; MITHRAMYCIN; MITOXANTRONE; MUTANT PROTEIN; NILOTINIB; PANOBINOSTAT; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; ROMIDEPSIN; TRANSCRIPTION FACTOR JUNB; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; WNT PROTEIN;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLAST CELL CRISIS; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOMES RESEARCH; PAIN; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHARMACOGENETICS; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; RNA ANALYSIS; RNA METHYLATION; THROMBOCYTOPENIA; WILD TYPE;

ANTINEOPLASTIC AGENTS; BETA CATENIN; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-JUN; TREATMENT OUTCOME; WNT PROTEINS;

EID: 40749154745     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.12.002     Document Type: Article

References (131)

1. Sokal J.E., Baccarani M., Russo D., et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25 (1988) 49-61
2. Clift R.A., Buckner C.D., Thomas E.D., et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 84 (1994) 4368-4373
3. Kantarjian H.M., Dixon D., Keating M.J., et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61 (1988) 1441-1446
4. Speck B., Bortin M.M., Champlin R., et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1 (1984) 665-668
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf accessed December 2007
6. Cortes J., Talpaz M., O'Brien S., et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 16 (1998) 3279-3285
7. Majlis A., Smith T.L., Talpaz M., et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14 (1996) 196-203
8. Kurzrock R., Gutterman J.U., and Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319 (1988) 990-998
9. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103 (2006) 2794-2799
10. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
11. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
12. Gleevec Package insert. East Hanover, NJ. Novartis Pharmaceuticals Corporation
13. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
14. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 (2006) 908-916
15. Atallah E., Durand J.-B., Kantarjian H., et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110 (2007) 1233-1237
16. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
17. Sacchi S., Kantarjian H.M., O'Brien S., et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86 (1999) 2632-2641
18. Giles F.J., Cortes J.E., Kantarjian H.M., et al. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am 18 (2004) 753-774 xii
19. Karbasian Esfahani M., Moris E.L., Dutcher J.P., et al. Blastic phase of chronic myelogenous leukemia. Curr Treat Options Oncol 7 (2006) 189-199
20. Deininger M., Schleuning M., Greinix H., et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 91 (2006) 452-459
21. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99 (2002) 1928-1937
22. Kantarjian H., Talpaz M., O'Brien S., et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-Comparison with historic experience. Cancer 103 (2005) 2099-2108
23. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99 (2002) 3530-3539
24. Ottmann O.G., Druker B.J., Sawyers C.L., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 (2002) 1965-1971
25. Lahaye T., Riehm B., Berger U., et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 103 (2005) 1659-1669
26. Cortes J., and Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 23 (2005) 6316-6324
27. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 340 (1999) 1330-1340
28. Elrick L.J., Jorgensen H.G., Mountford J.C., et al. Punish the parent not the progeny. Blood 105 (2005) 1862-1866
29. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
30. Roumiantsev S., Shah N.P., Gorre M.E., et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 99 (2002) 10700-10705
31. Kantarjian H.M., Talpaz M., O'Brien S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101 (2003) 473-475
32. Olsson-Stromberg U., Aleskog A., Bjornberg A., et al. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anticancer Drugs 17 (2006) 631-639
33. Hehlmann R., Heimpel H., Hasford J., and German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84 (1994) 4064-4477
34. Allan N.C., Richards S.M., and Shepherd P.C. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345 (1995) 1392-1397
35. Parmar S., and Platanias L.C. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 15 (2003) 431-439
36. Dowding C., Guo A.P., Osterholz J., et al. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78 (1991) 499-505
37. Bhatia R., McCarthy J.B., and Verfaillie C.M. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 87 (1996) 3883-3891
38. Cortes J., Fayad L., Kantarjian H., et al. Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 12 (1998) 455-462
39. Deng M., and Daley G.Q. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood 97 (2001) 3491-3497
40. Oka T., Sastry K.J., Nehete P., et al. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia 12 (1998) 155-163
41. Baccarani M., Martinelli G., Rosti G., et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104 (2004) 4245-4251
42. Quintas-Cardama A., Kantarjian H.M., Ravandi F., et al. Immune modulation of minimal residual disease (MRD) in patients (pts) with chronic myelogenous leukemia (CML) in early chronic phase (CP): A randomized trial of frontline high-dose (HS) imatinib mesylate (IM) with or without pegylated-interferon (PEG-IFN) and GM-CSF. Blood 11 (2006) 626a (abstr 2207)
43. Dauer M., Schmad K., Junkmann J., et al. IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. J Leukoc Biol 80 (2006) 278-286
44. Guerci A., Nicolini F., Maloisel F., et al. Randomized comparison of imatinib with imatinib combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase: Design and first interim analysis of a phase III trial from the French CML Group. Blood 11 (2005) 53a (abstr 168)
45. Guilhot F., Chastang C., Michallet M., and French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337 (1997) 223-229
46. Quintas-Cardama A., Kantarjian H., Ravandi F., et al. A pilot trial of imatinib, low-dose cytarabine (ara-C) and idarubicin (Ida) in patients (pts) with chronic myeloid leukemia (CML) in myeloid blastic phase (BP). Blood 11 (2005) 290a (abstr 4840)
47. Heidel F., Cortes J., Ruecker F., et al. Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C (LDAC) and imatinib. Blood 11 (2005) 527a (abstr 1853)
48. Carvajal R.D., Tse A., and Schwartz G.K. Aurora kinases: New targets for cancer therapy. Clin Cancer Res 12 (2006) 6869-6875
49. Harrington E.A., Bebbington D., Moore J., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10 (2004) 262-267
50. Cheetham G.M., Charlton P.A., Golec J.M., et al. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 251 (2007) 323-329
51. Giles F.J., Cortes J.E., Jones D., et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 11 (2006) 556a (abstr 1967)
52. Hoover R.R., and Harding M.W. Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with idarubicin, ara-C, and inhibitors of BCR-ABL. Blood 11 (2006) 403a (abstr 1384)
53. O'Brien S., Kantarjian H., Keating M., et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86 (1995) 3322-3326
54. Visani G., Russo D., Ottaviani E., et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 11 (1997) 624-628
55. O'Brien S., Giles F., Talpz M., et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98 (2003) 888-893
56. Scappini B., Onida F., Kantarjian H.M., et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 94 (2002) 2653-2662
57. Tipping A.J., Mahon F.X., Zafirides G., et al. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 16 (2002) 2349-2357
58. Quintás-Cardama A., Kantarrjian H., Garcia-Manero G., et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109 (2007) 1701-1707
59. Quintas-Cardama A., Kantarjian H.M., Wierda W., et al. A phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML). Blood 11 (2006) 616a (abstr 2174)
60. Porosnicu M., Nimmanapalli R., Nguyen D., et al. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 15 (2001) 772-778
61. Yang D., Zhang R., Shen Y., et al. Comparison of combination therapy of imatinib with trisenox versus imatinib monotherapy for chronic myeloid leukemia patients in chronic phase. Blood 11 (2006) 612a (abstr 2159)
62. Schnier J., Schwelberger H.G., Smit-McBride Z., et al. Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae. Mol Cell Biol 11 (1991) 3105-3114
63. Balabanov S., Gontarewicz A., Ziegler P., et al. Hypusination of eukaryotic initiation factor 5A (EIF-5A): A novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109 (2007) 1701-1707
64. Cortes J.E., O'Brien S.M., Giles F., et al. Investigational strategies in chronic myelogenous leukemia. ix. Hematol Oncol Clin North Am 18 (2004) 619-639
65. Fiskus W., Pranpat M., Bali P., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108 (2006) 645-652
66. George P., Bali P., Annavarapu S., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105 (2005) 1768-1776
67. Kano Y., Akutsu M., Tsunoda S., et al. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs 25 (2007) 31-40
68. Stover E.H., Chen J., Lee B.H., et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106 (2005) 3206-3213
69. Garcia-Manero G., Yang H., Bueso-Ramos C., et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2008) 1060-1066
70. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
71. Cortes J., Jabbour E., Daley G.Q., et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110 (2007) 1295-1302
72. Isaacs J.S., Xu W., and Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3 (2003) 213-217
73. George P., Bali P., Cohen P., et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 64 (2004) 3645-3652
74. Mayerhofer M., Valent P., Sperr W.R., et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100 (2002) 3767-3775
75. Ly C., Arechiga A.F., Melo J.V., et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 63 (2003) 5716-5722
76. Mohi M.G., Boulton C., Gu T.L., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 101 (2004) 3130-3135
77. Burchert A., Wng Y., Cai D., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19 (2005) 1774-1782
78. Kantarjian H.M., Talpaz M., Giles F., et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145 (2006) 913-923
79. Hughes T., and Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20 (2006) 29-41
80. White D., Saunders V., Lyons A.B., et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106 (2005) 2520-2526
81. ten Hoeve J., Arlinghaus R.B., Guo J.Q., et al. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 84 (1994) 1731-1736
82. White D.L., Saunders V.A., Dang P., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006) 697-704
83. Thomas J., Wang L., Clark R.E., et al. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 104 (2004) 3739-3745
84. Golemovic M., Verstovsek S., Giles F., et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11 (2005) 4941-4947
85. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
86. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
87. Verstovsek S., Golemovic M., Kantarjian H., et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104 (2005) 1230-1236
88. Tokarski J.S., Newit J.A., Chang C.Y., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66 (2006) 5790-5797
89. Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
90. Baccarani M., Kantarjian H.M., Apperley J.F., et al. Efficacy of dasatinib (Sprycel) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 'START-C' phase II study. Blood 108 (2006) 53a (abstr 164)
91. Dombret H., Ottmann O.G., Rosti G., et al. Dasatinib (SPRYCEL(R)) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): Updated results from the CA180-015 'START-L' study. Blood 11 (2006) 88a (abstr 286)
92. Martinelli G., Hochhaus A., Coutre S., et al. Dasatinib (SPRYCEL(R)) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (Im-r) or -intolerant (Im-i). Blood 11 (2006) 224a (abstr 745)
93. Cortes J., Kim D.W., Guilhot F., et al. Dasatinib (Sprycel) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): Updated results of the CA180-005 'START-A' phase II study. Blood 108 (2006) 613a (abstr 2160)
94. Guilhot F., Apperley J., Kim D.W., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
95. Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 (2007) 3207-3213
96. Weisberg E., Manley P., Mestan J., et al. AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 94 (2006) 1765-1769
97. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007) 3540-3546
98. Kantarjian H.M., Gattermann N., Hochhaus A., et al. A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). Blood 11 (2006) 615a (abstr 2169)
99. Kantarjian H. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood 11 (2006) 226a (abstr 735)
100. Coutre P.L. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance. Blood 11 (2006) 145a (abstr 471)
101. Giles F. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood 11 (2006) 310a (abstr 1025)
102. Larson R., Ottman O., Kantarjian H., et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory PH+ acute lymphoblastic leukemia (ALL). J Clin Oncol 25 (2007) 367s (abstr 7040)
103. Giles F., le Coutre P., Bhalla K., et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy. Blood 11 (2006) 645a (abstr 2170)
104. Gambacorti-Passerini C., Brummendorf T., Kantarjian H., et al. Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. J Clin Oncol 25 (2007) 18S (abstr 7006)
105. Craig A., Kantarjian H., Cortes J., et al. A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J Clin Oncol 25 (2007) 18S (abstr 7046)
106. Bonifazi F., de Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
107. Mahon F.X., Delbrel X., Cony-Makhoul P., et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20 (2002) 214-220
108. Branford S., Hughes T.P., and Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107 (1999) 587-599
109. Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
110. Merante S., Orlandi E., Bernasconi P., et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90 (2005) 979-981
111. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
112. Jorgensen H.G., Allan E.K., Graham S.M., et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19 (2005) 1184-1191
113. Nusse R., and Varmus H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31 (1982) 99-109
114. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 127 (2006) 469-480
115. Bresalier R.S. Malignant and premalignant lesions of the colon. In: Friedman S.L., McQuaid K.R., and Grendell J.H. (Eds). Current Diagnosis and Treatment in Gastroenterology. 2nd ed (2003), Lange Medical Books/McGraw-Hill, New York, NY 407-435
116. Rubinfeld B., Souza B., Albert I., et al. Association of the APC gene product with beta-catenin. Science 262 (1993) 1731-1734
117. Austin T.W., Solar G.P., Ziegler F.C., et al. A role for the Wnt gene family in hematopoiesis: Expansion of multilineage progenitor cells. Blood 89 (1997) 3624-3635
118. Van Den Berg D.J., Sharma A.K., Bruno E., et al. Role of members of the Wnt gene family in human hematopoiesis. Blood 92 (1998) 3189-3202
119. Kavalerchik E., Gotlib J., Geron I., et al. Inhibition of chronic myelogenous leukemia stem cells with novel Wnt antagonists. Blood 11 (2006) 74a (abstr 238)
120. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4 (2002) E131-E136
121. Schorpp-Kistner M., Wang Z.Q., Angel P., et al. JunB is essential for mammalian placentation. Embo J 18 (1999) 934-948
122. Passegue E., Jochum W., Schorpp-Kistner M., et al. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 104 (2001) 21-32
123. Yang M.Y., Liu T.C., Chang J.G., et al. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 101 (2003) 3205-3211
124. Bonifer C., Lefevre P., and Tagoh H. The regulation of chromatin and DNA-methylation patterns in blood cell development. Curr Top Microbiol Immunol 310 (2006) 1-12
125. de Vos D., and van Overveld W. Decitabine: A historical review of the development of an epigenetic drug. Ann Hematol 84 suppl (2005) 3-8
126. Issa J.P., Gharibyan V., Cortes J., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23 (2005) 3948-3956
127. La Rosee P., Johnson K., Corbin A.S., et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 103 (2004) 208-215
128. Calin G.A., and Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 6 (2006) 857-866
129. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 435 (2005) 834-838
130. He L., Thomson J.M., Hemann M.T., et al. A microRNA polycistron as a potential human oncogene. Nature 435 (2005) 828-833
131. Venturini L., Battmer K., Castoldi M., et al. The polycistronic miRNA cluster miR-17-92 is over-expressed in early phase chronic myeloid leukemia (CML) CD34+ cells. Blood 11 (2006) 223a (abstr 741)